Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: A review.
-Guilcher GMT, Shah R, Shenoy S. Pediatr Transplant. 2018 Mar;22(2). doi: 10.1111/petr. 13142. Epup 2018 Jan 19. Review
Curative therapies: Allogenic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
-Guilcher GMT, Truong TH, Saraf SL, Joseph JJ, Rondelli D, Hsieh MM. Semin Hematol. 2018 Apr;55(2): 87-93. doi: 10.1053/j.seminhematol.2018.04.011. Epub 2018 Apr 25. Review.
Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease.
-Abraham A, Hsieh M, Eapen M, Fitzhugh C, Carreras J, Keesler D, Guilcher G, Kamani N, Walters MC, Boelens JJ, Tisdale J, Shenoy S: National Institutes of Health; Centre for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2017 Dec;23(12):2178-2183.
doi: 10.1016/j.bbmt.2017.08.038. Epub 2017 Sep 4.
Hematopoietic Stem Cell Transplantation in Children and Adolescents.
-Guilcher GM Pediatr Rev. 2016 Apr;37(4):135-44; quiz 145. doi: 10.1542/pir.2015-0044. No abstract available.
Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children’s Oncology Group Report.
-Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GM, Huang JT, Pelletier W, Perkins JL, Rivard LS, Schechter T, Shah AJ, Wilson KD, Wong K, Grewal SS, Armenian SH, Meacham LR, Mulrooney DA, Castellino SM. Biol Blood Marrow Transplant. 2016 May;22(5):782-95. Doi: 10.1016/j.bbmt.2016.01.023. Epub 2016 Jan 21. Review.